The Chinese Veterinary Pharmacopoeia 2020 monograph for Yimu Shenghua Powder defines a six-herb matrix consisting of Leonurus japonicus aerial herb, Angelica sinensis root, Ligusticum chuanxiong rhizome, Prunus persica seed, Zingiber officinale rhizome, and Glycyrrhiza uralensis root and rhizome. In transition-cow feeding systems, the powder is introduced after the mineral premix weigh-hopper and not during steam conditioning, because extended heat and moisture input degrade the less thermostable marker compounds. The CVP oral dose for cattle as 250–500 g/head/day is used to calculate feed inclusion. At 20 kg dry matter intake, this equals 1.25–2.50% of daily DM. In a 2 kg transition-cow concentrate offered daily, the addition ratio is 125–250 g/kg, equivalent to 12.5–25.0% w/w. A direct top-dress premix of 500 g per cow per day is not commonly used because it would require 50–100% w/w active material; the powder is therefore supplied as a direct oral powder or as a high-concentration medicated premix for feed mills rather than a low-inclusion additive. Mixing is performed in a 2,000 L horizontal double-ribbon mixer at 18–25 rpm shaft speed for 12–15 min; the release criterion is a coefficient of variation of marker compound distribution ≤7% across 10 ISO 6497:2002 probe samples. Sieve retention on 180 µm mesh is controlled because coarser botanical particles segregate against limestone and salt carriers during augering. The terminal finished product types are registered medicated premixes, oral powders, and custom transition-ration concentrates. Compliance boundaries are CVP 2020 monograph general tests, China Good Manufacturing Practice for Veterinary Drugs line-clearance and carryover control, and ISO 6498:2012 sample preparation. In destination markets, EU Regulation 1831/2003 does not permit this plant-based veterinary API to be classified as a feed additive, so feed-route claims remain within the registered veterinary medicinal product pathway.

What Limits a Sow Soluble Powder’s Stability in Automated Drinking-Water Dosing Lines?

Water-route processing of the API is not a wet granulation of the raw botanical matrix, but a dry blending operation with a fully water-dispersible carrier. The API is first passed through a pin mill to a particle-size distribution D90 ≤75 µm, measured by laser diffraction per ISO 13320:2020, then blended with dextrose monohydrate and 0.15% anhydrous citric acid. The sow dose follows CVP oral dosage of 30–60 g/head/day. At 8–12 L daily water intake, the required drinking-water concentration is 0.25–0.75% w/v. In a 1:100 proportioner dosing system, a stock solution of 3–6 kg/100 L is prepared, and a 1,000-sow barn consumes 30–60 kg powder per day. Sedimentation is the critical failure mode: lignocellulosic residues from the botanical matrix settle in pipeline sections where flow velocity drops below 0.45 m/s, causing check-valve fouling and biofilm seeding in dead legs. The terminal product is packaged in HDPE drums with desiccant sachets or water-soluble sachets, after moisture content is reduced to ≤5%. The compliance boundary includes CVP 2020 microbial limits, uniformity of mass, and suspensibility, plus source-water pH 7.0–7.4 and calcium carbonate below 180 mg/L, because hard water precipitates polyphenolic markers and destabilizes the dispersion. Clean-in-place with 0.1% peracetic acid at 20°C for 15 min is required before each production batch to control microbial carryover from carbohydrate carriers.

Comparative process and compliance matrix for downstream routes:

When Tablet Compression Must Accommodate Batch-to-Batch Flow Variability in Botanical API

Direct compression of the raw six-herb powder is avoided because the angle of repose regularly exceeds 40° and tapped bulk density shifts from 0.35 g/mL to 0.55 g/mL across harvest years. The standard route is dry granulation through a roller compactor with 1.0 mm screen, followed by blending with microcrystalline cellulose, crospovidone 2–4%, and sodium starch glycolate 1–2%. In a 500 mg film-coated tablet containing 120 mg of a 5:1 extract, the API addition ratio is 24% w/w of the core. The equivalent crude powder per tablet is 600 mg, so the CVP sheep/goat/swine oral dose of 30–60 g crude powder/day corresponds to 50–100 tablets if used as the sole route, which is impractical in field use; therefore tablet applications are positioned for weight-adjusted veterinary regimens and small-animal compounding where the lower crude-equivalent dose is specified by the prescribing veterinarian. Compression is performed on a 27-station rotary tablet press at 35–50 rpm with compression force 12–18 kN; release limits are friability ≤1.0% per USP <1217>, hardness 60–90 N, and disintegration time ≤30 min in purified water at 37°C per USP <701>. For capsule filling, size 0 or 1 hard gelatin capsules are filled on a dosator machine, and powder moisture is held at 4.0–5.5% to prevent dosator plugging. The terminal product types are uncoated tablets, film-coated tablets, and hard capsules for veterinary clinics. A documented formulation incompatibility is magnesium or sodium stearate above 1.0%, which forms a hydrophobic film on botanical particles and can extend disintegration beyond the 30 min limit when tablet hardness is at the upper end. Compliance includes USP <1217>, USP <701>, and CVP 2020 limits for heavy metals and microbial load; capsules require TSE/BSE declarations for gelatin and residual ethylene oxide testing where EP 5.1.4 is applied in the importing jurisdiction.

Injectable-grade processing of the multi-botanical powder begins with countercurrent reflux extraction in a 3,000 L multi-effect unit at 85–95°C for 1.5–2.0 h per pass, followed by high-speed centrifugation at 10,000×g and 0.45 µm polyethersulfone membrane clarification. The clarified extract is concentrated under vacuum at 55–60°C and freeze-dried to produce an injectable-grade dry extract. A 5:1 extract ratio, meaning 5.0 kg crude powder yields 1.0 kg dry extract, is used as the starting formulation basis; the final ratio is adjusted by HPLC assay of the selected marker because multi-herb extraction efficiency varies by harvest. The terminal product is a sterile aqueous injection in 10–50 mL Type II glass vials. Where extract stability permits, terminal sterilization is applied at 121°C for 15 min; otherwise, the solution is filtered through 0.22 µm PVDF membrane and filled aseptically. Endotoxin control is the main critical threshold: the bulk solution must test ≤0.5 EU/mL by USP <85>, and particulate matter must meet USP <788>. Sterility assurance follows USP <71>. A specific operational boundary is that autoclaving a raw unfiltered powder suspension is not acceptable because insoluble fibers and starches precipitate after heating and may occlude 21-gauge needles. Pharmacokinetic and target-animal safety data for this specific injectable multi-herb configuration remain limited, so dose-finding for injection must not be assumed from oral CVP doses without veterinary bioequivalence evaluation.

Oral Drench Suspension Parameters, Syringeability, and Flock Treatment Throughput

For adult cattle oral drench administration, the powder is dispersed in 0.5% xanthan gum vehicle at 250 g/L, passed through an inline 1.0 mm strainer, and filled into 1 L drenching containers. The CVP cattle dose of 250–500 g crude powder/day is supplied as 1–2 L of suspension per day, delivered with a 60 mL or 500 mL repeat-fill drench gun. The finished product is a preservative-free suspension concentrate for extemporaneous dilution; once reconstituted, it must be used within 24 h at 2–8°C, because the aqueous vehicle has no preservative and microbial growth in field conditions is the main limitation. Release tests include CVP 2020 oral liquid microbial limits and USP <51> preservative challenge where a preserved variant is requested. The terminal product type is an oral suspension for large-animal veterinary use.